The level of cancer risk associated to PALB2 pathogenic variants is known to be low in comparison to BRCA2 pathogenic variants, but enough to propose a clinical management of the familly contrary to other low risk genes, notably CHEK2 1100delC and ATM [44]. This evidence concerns the gene BRCA2 and cancer.